Literature DB >> 10602748

Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics.

M Tanaka1, H Nakayama, M Haraoka, T Saika, I Kobayashi, S Naito.   

Abstract

We examined the antimicrobial susceptibilities of 85 Neisseria gonorrhoeae isolates, classified according to the presence of amino acid substitutions in the GyrA and ParC proteins, to 12 fluoroquinolones and 7 other antibiotics. Sitafloxacin and HSR-903 showed excellent activity against N. gonorrhoeae, including strains with both GyrA and ParC substitutions. Among the strains with various GyrA substitutions, strains with a serine-91-to-phenylalanine mutation required the highest MICs of all of the fluoroquinolones tested and were cross-resistant to structurally unrelated beta-lactams.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10602748      PMCID： PMC89653          DOI： 10.1128/AAC.44.1.192-195.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  High-level quinolone resistance in Neisseria gonorrhoeae: a report of two cases.

Authors:  J W Tapsall; E A Limnios; C Thacker; B Donovan; S D Lynch; L J Kirby; K A Wise; C J Carmody
Journal:  Sex Transm Dis       Date:  1995 Sep-Oct       Impact factor: 2.830

2.  Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.

Authors:  M Nakashima; T Uematsu; K Kosuge; K Umemura; H Hakusui; M Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 3.  The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Haemophilus ducreyi.

Authors:  C A Ison; J A Dillon; J W Tapsall
Journal:  Lancet       Date:  1998       Impact factor: 79.321

4.  Antimicrobial resistance in Neisseria gonorrhoeae in the United States, 1988-1994: the emergence of decreased susceptibility to the fluoroquinolones.

Authors:  K K Fox; J S Knapp; K K Holmes; E W Hook; F N Judson; S E Thompson; J A Washington; W L Whittington
Journal:  J Infect Dis       Date:  1997-06       Impact factor: 5.226

5.  Transcriptional control of the mtr efflux system of Neisseria gonorrhoeae.

Authors:  K E Hagman; W M Shafer
Journal:  J Bacteriol       Date:  1995-07       Impact factor: 3.490

6.  Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the GyrA mutation. The Pazufloxacin STD Group.

Authors:  M Tanaka; T Matsumoto; M Sakumoto; K Takahashi; T Saika; I Kabayashi; J Kumazawa
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.

Authors:  T Deguchi; M Yasuda; M Nakano; S Ozeki; T Ezaki; I Saito; Y Kawada
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

8.  Analysis of quinolone resistance mechanisms in a sparfloxacin-resistant clinical isolate of Neisseria gonorrhoeae.

Authors:  M Tanaka; H Nakayama; M Haraoka; T Nagafuji; T Saika; I Kobayashi
Journal:  Sex Transm Dis       Date:  1998-10       Impact factor: 2.830

9.  Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates.

Authors:  R J Belland; S G Morrison; C Ison; W M Huang
Journal:  Mol Microbiol       Date:  1994-10       Impact factor: 3.501

10.  Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus.

Authors:  M J Gill; S Simjee; K Al-Hattawi; B D Robertson; C S Easmon; C A Ison
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191
  10 in total
  8 in total

1.  Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region.

Authors:  S M Friedman; T Lu; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Mutation patterns in gyrA and parC genes of ciprofloxacin resistant isolates of Neisseria gonorrhoeae from India.

Authors:  U Chaudhry; K Ray; M Bala; D Saluja
Journal:  Sex Transm Infect       Date:  2002-12       Impact factor: 3.519

3.  Molecular characterization of quinolone-resistant Neisseria gonorrhoeae in Hong Kong.

Authors:  Kai Man Kam; Shirley Sin Yee Kam; Danny Tze Leung Cheung; Viola Wai Na Tung; Wai Fun Au; May May Cheung
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

4.  Disseminated gonococcal infection in an immunocompetent patient caused by an imported Neisseria gonorrhoeae multidrug-resistant strain.

Authors:  Ivano Dal Conte; Stefania Starnino; Giovanni Di Perri; Paola Stefanelli
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

Review 5.  Gatifloxacin: a review of its use in the management of bacterial infections.

Authors:  Caroline M Perry; Douglas Ormrod; Miriam Hurst; Susan V Onrust
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.

Authors:  T R Shultz; J W Tapsall; P A White
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  In vitro assessment of the further potential for development of fluoroquinolone resistance in Neisseria meningitidis.

Authors:  Tiffany R Shultz; Peter A White; John W Tapsall
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

8.  Mosaic-like structure of penicillin-binding protein 2 Gene (penA) in clinical isolates of Neisseria gonorrhoeae with reduced susceptibility to cefixime.

Authors:  Satoshi Ameyama; Shoichi Onodera; Masahiro Takahata; Shinzaburo Minami; Nobuko Maki; Katsuhisa Endo; Hirokazu Goto; Hiroo Suzuki; Yukihiko Oishi
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.